Joint statement
The forth update of the Joint Statement offers a general update, the latest on treatments as well as new information on COVID-19 in PID patients.
IPOPI is committed to monitor closely the COVID-19 pandemic and to share evidence-based and expert validated information to the global primary immunodeficiency (PID) patients community and to our stakeholders.
The situation is evolving rapidly all over the world with new restrictions being imposed in an increasing number of countries. Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic. IPOPI has been engaging on several fronts to fast track the publication of statements, answer frequently asked questions and participate in international efforts to collect data on COVID-19 in PIDs.
This page aggregates all of IPOPI’s efforts and selected external statements.
IPOPI commits to publish and update its statements as the situation evolves. Please always refer to the latest statement which contains up to date recommendations.
IPOPI published a Joint Statement together with ESID, INGID, APSID, ARAPID, ASID, CIS, LASID and SEAPID on the COVID-19 epidemics. Covers general and PID specific precautions and advises monitoring regional public advices.
IPOPI has gathered the most pressing COVID-19 and PIDs questions received from our National Member Organisations (NMOs) into a FAQs page. Stay tuned for further updates!
IPOPI launched the COVID-19 Learning Expedition (LEX) in July 2020, to identify, analyse and provide recommendations on issues brought about by the COVID-19 pandemic for patients with primary immunodeficiency (PID).
IPOPI sent a letter to the APEC Bloof and Policy Forum representatives highlighting the importance of ensuring blood/plasma/PDMP supply during current COVID-19
IPOPI just published an Open Letter calling international, regional and national authorities to ensuring sufficient blood and plasma supply during and after the COVID-19 outbreak.
IPOPI is participating in the launch of a global survey on COVID-19 and PIDs, working jointly with International Union of Immunological Societies (IUIS) and other medical societies.
The survey is now entering phase 2 – please help us by sharing it with national medical advisers and all national doctors who you know are managing PID patients in your country:
Please find external helpful resources and updated information on the COVID-19 outbreak.
UK
Rocky Bottom, Trerieve, Downderry, PL11 3LY, UK
IPOPI is a non-profit charity registered in the UK
Charity number 1058005
Belgium
Avenue Louise/Louizalaan 367
BE-1050 Brussels, Belgium
IPOPI aisbl is an international non-profit association registered in Belgium
Numéro d’entreprise
BE 0761.784.055
Portugal – Executive office
Av. Aida, Bloco 8, escritório 821
2765-187 Estoril, Portugal
Email: info@ipopi.org
Tel: +44 1503 250 668/961 (UK)
+351 21 407 5720 (Portugal)